Uterine surveillance of asymptomatic postmenopausal women taking tamoxifen

Climacteric

Volumn 1, Issue 3, 1998, Pages 180-187

  Gardner, F J E ^a   Konje, J C ^a   Brown, L ^a   Khanna, S ^a   Bell, S C ^a   Taylor, D J ^a   Al Azzawi, F ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Endometrium; Hysteroscopy; Screening; Tamoxifen; Transvaginal sonography

Indexed keywords

TAMOXIFEN;

ARTICLE; CHEMICALLY INDUCED DISORDER; CURETTAGE; CYST; ECHOGRAPHY; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HYSTEROSCOPY; LEIOMYOMA; MIDDLE AGED; PATHOLOGY; POLYP; POSTMENOPAUSE; UTERUS CANCER; UTERUS DISEASE;

CURETTAGE; CYSTS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; FEMALE; HUMANS; HYSTEROSCOPY; LEIOMYOMA; MIDDLE AGED; POLYPS; POSTMENOPAUSE; TAMOXIFEN; UTERINE DISEASES; UTERINE NEOPLASMS;

EID: 0032169517     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.3109/13697139809085539     Document Type: Article

References (28)

1. Early Breast Cancer Trialist's Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31 000 recurrences and 2400 deaths in 75 000 women. 1. Lancet 1992;339:71-85
2. Lahti E, Vuopala S, Kauppila A, et al. Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen. Gynecol Oncol 1994;55: 410-14
3. Webster NJ, Green S, Jin JR, et al. The hormone binding domains of the oestrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 1988;54: 199-207
4. Berry M, Metzger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 1990;9:2811-18
5. Mosselman S, Polman J, Dijkema R. ERβ: identification and characterisation of a novel human estrogen receptor. FEBS Lett 1996;392:49-53
6. Webb P, Lopez GN, Uht RM, et al. Tamoxifen activation of the oestrogen receptor/AP-1 pathway: potential origin for the cell-specific oestrogen-like effects of anti-oestrogens. Mol Endocrinol 1995;9:443-56
7. Assikis VJ, Neven P, Jordan VC. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996;32A:1464-76
8. Fisher B, Constantino JP, Redmond CK. Endometrial cancer in tamoxifen treated breast cancer patients. Findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst 1994;86:527-37
9. Kedar RP, Bourne TH, Powles TJ. Effect of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994;343: 1318-21
10. Neven P, Vergote I. Should tamoxifen users be screened for endometrial lesions? Lancet 1998; 351:155-6
11. Fleischer AC, Kaiemaris G, Machin JE. Sonographic depiction of normal and abnormal endometrium with histopathologic correlation. J Ultrasound Med 1986;5:445-52
12. Fleischer AC, Kalemaris G, Entman S. Sonographic depiction of the endometrium during normal cycles. Ultrasound Med Biol 1986;12: 271-7
13. Downes E, Al-Azzawi F. How well do menopausal patients accept outpatient hysteroscopy? Visual analogue scoring of acceptability and pain in 100 women. Eur J Obstet Gynecol 1993;48: 37-41
14. Love RR. Tamoxifen in healthy premenopausal women: different risks and benefits. J Natl Cancer Inst 1994;86:62-3
15. Neven P, DeMuylder X. Tamoxifen and the uterus. Br Med J 1994;309:1313-14
16. Fleischer AC, Dudley BS, Entman SS. Myometrial invasion by endometrial carcinoma: sonographic assessment. Radiology 1987;162:307-10
17. Nasri MN, Coast GJ. Correlation of ultrasound findings and endometrial histopathology in postmenopausal women. Br J Obstet Gynecol 1989; 96:1333-8
18. Anteby E, Yagel S, Zamt D. False sonographic appearance of endometrial neoplasia in postmenopausal women treated with tamoxifen. Lancet 1992;340:433-4
19. Hulka CA, Hall DA. Endometrial abnormalities associated with tamoxifen therapy for breast cancer: sonographic and pathologic correlation. Am J Roentgenol 1993;160:809-12
20. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994;170:447-51
21. Downes E, Al-Azzawi F. The predictive value of outpatient hysteroscopy in a menopause clinic. Br J Obstet Gynecol 1993;100:1148-9
22. Akkad A, Habiba MA, Ismail N. Abnormal uterine bleeding on hormone replacement: the importance of intrauterine structural abnormalities. Obstet Gynecol 1991;77:745-8
23. Al-Azzawi F, Habiba M, Bell SC. The Leicester Endometrial Needle Sampler: a novel device for endometrial and myometrial junctional zone biopsy. Obstet Gynecol 1997;90:470-2
24. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994;47:827-33
25. Shaw RW, Souter WP, Stanton SL, eds. Gynecology 2nd edn. Edinburgh: Churchill Livingstone, 1997:535-9
26. Achiron R, Grisaru D, Golan-Porat N. Tamoxifen and the uterus: an old drug tested by new modalities. Ultrasound Obstet Gynecol 1996;7: 374-8
27. Cecinelli E, Romano F, Anastasio PS, et al. Sonohysterography versus hysteroscopy in the diagnosis of endouterine polyps. Gynecol Obstet Invest 1994;38:266-71
28. Widrich T, Bradley LD, Mitchinson AR, et al. Comparison of saline infusion sonography with office hysteroscopy for the evaluation of the endometrium. Am J Obstet Gynecol 1996;174: 1327-34